Yazar "Ercan, F." seçeneğine göre listele

Listeleniyor 1 - 6 / 6
  • Küçük Resim Yok
    Öğe
    Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?
    (7847050 Canada Inc, 2019) Purut, Y. E.; Buyukbayrak, E. E.; Ercan, F.; Orcun, A.; Menke, M.; Karsidag, A. Y. Karageyim
    Purpose of Investigation: The aim of this study is to evaluate whether first trimester maternal serum follistatin like 3 (FSTL3) levels can be used to predict preeclampsia and related obstetric complications. Materials and Methods: The serum levels of FSTL3, pregnancy associated plasma protein A (PAPP-A), and free beta-hCG were determined in the first trimester from a sample of 180 pregnant women. All patients had first- and second-trimester ultrasound evaluations. The pregnancy outcome was defined as 'adverse' if one of the following outcomes were observed: fetal death, preeclampsia, pregnancy-induced hypertension (PIH), delivery of a small infant for gestational age (SGA) or preterm delivery. Results: FSTL3 levels were not significantly different for preeclampsia and related adverse obstetric outcomes compared to the control group (p < 0.05). Only PAPP-A MoM values were lower in the adverse obstetric outcome group than in the control (p = 0.040). There was no significant association among FSTL3 levels and the presence of any complications, according to our ROC curve analyses (p = 0.846). Conclusions: First trimester FSTL3 levels are not predictive for preeclampsia or adverse pregnancy outcomes.
  • Küçük Resim Yok
    Öğe
    Do first trimester maternal serum follistatin like 3 levels predict preeclampsia and/or related adverse pregnancy outcomes?
    (7847050 Canada Inc, 2019) Purut, Y. E.; Buyukbayrak, E. E.; Ercan, F.; Orcun, A.; Menke, M.; Karsidag, A. Y. Karageyim
    Purpose of Investigation: The aim of this study is to evaluate whether first trimester maternal serum follistatin like 3 (FSTL3) levels can be used to predict preeclampsia and related obstetric complications. Materials and Methods: The serum levels of FSTL3, pregnancy associated plasma protein A (PAPP-A), and free beta-hCG were determined in the first trimester from a sample of 180 pregnant women. All patients had first- and second-trimester ultrasound evaluations. The pregnancy outcome was defined as 'adverse' if one of the following outcomes were observed: fetal death, preeclampsia, pregnancy-induced hypertension (PIH), delivery of a small infant for gestational age (SGA) or preterm delivery. Results: FSTL3 levels were not significantly different for preeclampsia and related adverse obstetric outcomes compared to the control group (p < 0.05). Only PAPP-A MoM values were lower in the adverse obstetric outcome group than in the control (p = 0.040). There was no significant association among FSTL3 levels and the presence of any complications, according to our ROC curve analyses (p = 0.846). Conclusions: First trimester FSTL3 levels are not predictive for preeclampsia or adverse pregnancy outcomes.
  • Küçük Resim Yok
    Öğe
    Prenatal diagnosis of ring chromosome 4 and Wolf-Hirschorn syndrome with bilateral polycystic kidney disease
    (Nature Publishing Group, 2019) Tasdemir, P.; Gultekin, N. D.; Ercan, F.; Yilmaz, F. H.; Acar, A.; Altunhan, H.
    [Abstract Not Availabe]
  • Küçük Resim Yok
    Öğe
    Risk for Malignant and Borderline Ovarian Neoplasms Following Basic Preoperative Evaluation by Ultrasonography, Ca125 Level and Age
    (Asian Pacific Organization Cancer Prevention, 2014) Karadag, Burak; Kocak, M.; Kayikcioglu, F.; Ercan, F.; Dilbaz, B.; Kose, M. F.; Haberal, A.
    Objective: To verify the basic preoperative evaluation in the discrimination between benign and malignant adnexal masses in our clinical practice. Materials and Methods: Data were collected on the records of 636 women with adnexal masses who had undergone surgery either by open or endoscopic approaches. Those with obvious signs of malignancy, any history of cancer, emergency surgeries without basic evaluation were excluded. The preoperative features by age, ultrasound and serum Ca125 level were compared with final histopathological diagnosis at the four departments of the institution. These are the general gynecology (Group 1:exploratory laparotomy), the gynecologic endoscopy (Group 2: laparoscopy and adnexectomy), the gynecological oncology (Group 3:staging laparotomy) and the gynecologic endocrinology and infertility (Group 4: laparoscopy and cystectomy). Results: There were simple and complex cyst rates of 22.3% and 77.2%, respectively. There were 86.3% benign, 4.1% (n:20) borderline ovarian tumor (BOT) and 6.4% (n:48) malignant lesions. There were 3 BOT and 9 ovarian cancers in Group 1 and one BOT and two ovarian cancer in the Group 2. During the surgery, 15 BOT (75%) and 37 ovarian cancer (77%) were detected in the Group 3, only one BOT was encountered in the Group 4. The risk of rate of unsuspected borderline or focally invasive ovarian cancer significantly increased by age, size, complex morphology and Ca125 (95% CI, OR=2.72, OR=6.60, OR=6.66 and OR=4.69, respectively). Conclusions: Basic preoperative evaluation by comprehensive ultrasound imaging combined with age and Ca125 level has proved highly accurate for prediction of unexpected malignancies. Neither novel markers nor new imaging techniques provide better information that allow clinicians to assess the feasibility of the planned surgery; consequently, the risk of inadvertent cyst rupture during laparoscopy may be significantly decreased in selected cases.
  • Küçük Resim Yok
    Öğe
    A safe procedure for myomectomy during cesarean section
    (7847050 Canada Inc, 2019) Ercan, F.; Pekin, A.; Sarikaya, M.; Kilic, F.; Balci, O.; Gorkemli, H.; Acar, A.
    Purpose of Investigation: A retrospective cohort study was performed to identify whether myomectomy at the time of cesarean delivery leads to an increased risk of intrapartum and short-term postpartum complications. The authors' aim is to investigate the short-term outcomes of women who have undergone a cesarean myomectomy.Materiais and Methods: This study included the cases that had undergone cesarean myomectomy between January, 2008 and December, 2015. Two hundred twenty-seven pregnant women with uterine myomas who delivered via cesarean section were identified. One hundred two women underwent cesarean myomectomy. The authors compared the maternal characteristics, type of myomas, neonatal weight, and operative outcomes between the two groups. Results: Two group analysis revealed that there were no significant differences in the mean hemoglobin change (1.5 +/- 1.0 vs. 1.2 +/- 0.9 mg/dL), and the length of hospital stay (3.9 +/- 1.2 vs. 3.3 +/- 1.4 days) between two groups. The operative time of myomectomy group was significantly longer (88.5 +/- 19.5 vs. 58.0 +/- 20.4 min, p <0,01), No patient in either group required hysterectomy or embolization. Conclusions: Myomectomy during cesarean delivery does not appear to result in an increased risk of intrapartum or short-term postpartum morbidity.
  • Küçük Resim Yok
    Öğe
    A safe procedure for myomectomy during cesarean section
    (7847050 Canada Inc, 2019) Ercan, F.; Pekin, A.; Sarikaya, M.; Kilic, F.; Balci, O.; Gorkemli, H.; Acar, A.
    Purpose of Investigation: A retrospective cohort study was performed to identify whether myomectomy at the time of cesarean delivery leads to an increased risk of intrapartum and short-term postpartum complications. The authors' aim is to investigate the short-term outcomes of women who have undergone a cesarean myomectomy.Materiais and Methods: This study included the cases that had undergone cesarean myomectomy between January, 2008 and December, 2015. Two hundred twenty-seven pregnant women with uterine myomas who delivered via cesarean section were identified. One hundred two women underwent cesarean myomectomy. The authors compared the maternal characteristics, type of myomas, neonatal weight, and operative outcomes between the two groups. Results: Two group analysis revealed that there were no significant differences in the mean hemoglobin change (1.5 +/- 1.0 vs. 1.2 +/- 0.9 mg/dL), and the length of hospital stay (3.9 +/- 1.2 vs. 3.3 +/- 1.4 days) between two groups. The operative time of myomectomy group was significantly longer (88.5 +/- 19.5 vs. 58.0 +/- 20.4 min, p <0,01), No patient in either group required hysterectomy or embolization. Conclusions: Myomectomy during cesarean delivery does not appear to result in an increased risk of intrapartum or short-term postpartum morbidity.